NCT06705335Recruiting
Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma
Convertases and Pancreatic Cancer. New Therapeutic and Prognostic Approach: Cohort of Patients Treated for Pancreatic Adenocarcinoma (CONVERCAP)
Source: ClinicalTrials.gov · Last updated 20 Apr 2026
Brief summary (registry, in English)
This is a prospective, single-centre, observational study. The analysis of samples of pancreatic tumours and/or metastases taken during biopsy or surgery will lead to the determination of the level of expression of convertases in patients with pancreatic cancer and could be used as an additional prognostic means reinforcing those currently used.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 22 Nov 2024
- Start date
- 27 Mar 2026
- Primary completion date
- 31 Jan 2028
- Lead sponsor
- Institut Bergonié
- Diseases
- Pancreatic cancer
- NCT number
- NCT06705335
What you commit to
- Study type: Observational
- Planned participants: 50
- From 27 Mar 2026 to the primary completion date, 31 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Indication for biopsy for primary diagnosis of pancreatic cancer
- No indication for treatment of pancreatic cancer.
- Adjuvant/neoadjuvant chemotherapy completed less than 6 months ago in the case of patients with recurrent disease.
Other
- Patient already included in the study.
- Geographical, social or psychological factors rendering the patient unable to undergo study monitoring and procedures.
Who the study is looking for
- Age ≥ 18 years.
- Pancreatic adenocarcinoma (suspected on radiological assessment or histologically proven):
- Indication for biopsy of metastasis(es) performed as part of standard care for patients who already have a histologically confirmed diagnosis of pancreatic cancer.
- Indication for pancreatic surgery or metastasis(es) carried out as part of standard care for patients with a suspicion of pancreatic cancer on radiological assessment or who already have a confirmed histological diagnosis of pancreatic cancer.
- Whatever the stage of the disease.
- Whatever the type of treatment proposed (systemic, surgery, radiotherapy, etc.).
- Patient who has never received systemic treatment or advanced radiotherapy.
- WHO 0-1-2.
- Life expectancy \> 3 months.
- Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).
- Patient affiliated to a social security scheme in compliance with Article 1121-11 of the French Public Health Code.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Bergonié, Comprehensive Cancer Center Coordinator of this site? Confirm its status | Bordeaux | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.